Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (551) clinical trials

Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease

Rationale Today's aging population brings an increase in the incidence of dementia. In Canada, there are approximately 564,000 persons diagnosed with dementia, with an expected two-fold increase in this number by the year 2031. In this context, the early detection and prediction of cognitive decline are both imperative for achieving ...

Phase N/A

National Bank Alzheimer

The Alzheimer's disease (MY) is a major problem of public health. The French National Database Alzheimer ( BNA) registers(records) all the medical acts made by units of memory(report) and of independent specialists in France. In 2008, the national Plan Alzheimer 2008 - 2012 had for objective to strengthen the search(research) ...

Phase N/A

Age-related Hearing Loss and Lexical Disorders

In France, Alzheimer's disease accounts for 70 to 80% of the causes of neurocognitive disorders, i.e. 600,000 to 800,000 patients. It is a neurodegenerative pathology that causes evolutionary cognitive dysfunction, mainly affecting memory functions. The inability to name familiar objects (lack of the word) is one of the most commonly ...

Phase N/A

The Healthy Patterns Study

Over 5 million Americans have Alzheimer's disease or a related dementia, a progressive and fatal neurodegenerative condition, affecting close to 15 million family caregivers (CG). Circadian rhythm disorders (CRDs) occur in the majority of persons with dementia and include late afternoon/evening agitation (e.g. sundowning) and irregular sleep-wake rhythms such as ...

Phase

Safety and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled study of a new buccal film of montelukast in patients with mild to moderate Alzheimer's Disease. Study drug (10-mg montelukast or matching placebo) will be administered once daily for 26 weeks, and treatment effect will be assessed primarily using the global ...

Phase

Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells

LO-MAPT will also assess the effect of an audiovisual aid, compared with traditional paper participant information sheet only, on participants' understanding of the protocol, as well as on drop-out, adherence and clinical outcome in older adults at risk of cognitive decline. In addition to the main LO-MAPT study procedures, in ...

Phase

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

Approximately 88 subjects are planned to be enrolled for the entire study. Initially, approximately 30 subjects will be randomized via a centralized interactive response technology (IRT) in a 1:2 ratio (ie, approximately 10 and 20 subjects) to receive placebo and 60 mg AD-35. The Data Safety Monitoring Board (DSMB) will ...

Phase

DC Longitudinal Study on Aging and Specimen Bank

These studies will examine the feasibility of using various biochemical assays in blood, and/or cerebrospinal fluid, genetic testing, cognitive status assessments, and lifestyle questionnaires to aid in the ante-mortem diagnosis of Alzheimer's and other neurodegenerative diseases. Subjects have 2 options for participation. They may solely participate in the main study ...

Phase N/A

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD). This Phase 2 study is designed to evaluate the safety of two doses of CT1812 administered once daily for 6 months ...

Phase

A Pharmacodynamics Safety and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers

This is a double-blind, 3-arm, parallel group study of 15 days duration including a scopolamine challenge at D15. Healthy male subjects will receive daily doses of THN201 (donepezil 5 mg and mefloquine), donepezil 5 mg or placebo and one subcutaneous injection of scopolamine 0.5 mg on D15. Cognitive function, EEG ...

Phase